Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.

@article{Zivin2013EvaluationOT,
  title={Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.},
  author={Kara Zivin and Paul N. Pfeiffer and Amy S. B. Bohnert and Dara Ganoczy and Frederic C. Blow and Brahmajee K. Nallamothu and Helen C. Kales},
  journal={The American journal of psychiatry},
  year={2013},
  volume={170 6},
  pages={642-50}
}
OBJECTIVE A recent Food and Drug Administration (FDA) warning cautioned that citalopram dosages exceeding 40 mg/day may cause abnormal heart rhythms, including torsade de pointes. The authors assessed relationships between citalopram use and ventricular arrhythmias and mortality. METHOD A cohort study was conducted using Veterans Health Administration data between 2004 and 2009 from depressed patients who received a prescription for citalopram (N=618,450) or for sertraline (N=365,898), a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 25 times over the past 90 days. VIEW TWEETS